Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | MTTP | P55157 | 6/20 | 0.46 |
| ▸ | APOB | P04114 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789743 | 0.91 | SMO (0.58) | SMOMTTPAPOBTRPV1GAA | |
| SCHEMBL6504077 | 0.89 | SMO (0.48) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6490917 | 0.88 | TRPV1 (0.47) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6490835 | 0.88 | SMO (0.50) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6497088 | 0.87 | HTR2C (0.51) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6802784 | 0.86 | SMO (0.51) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6488178 | 0.83 | SMO (0.52) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6502553 | 0.82 | SMO (0.51) | SMOMTTPAPOBTRPV1NR3C1 | |
| SCHEMBL6795346 | 0.82 | SMO (0.59) | SMOMTTPAPOBTRPV1GAA | |
| SCHEMBL6497042 | 0.81 | SMO (0.49) | SMOMTTPAPOBTRPV1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885MTTP 677/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.